Clinical Research Directory

PROACT Pilot Trial

Sponsor: University of British Columbia

Summary

Kidney transplantation is considered the best option to treat end-stage kidney disease, but the recipient's immune system may respond with rejection to the transplanted organ, leading to permanent kidney damage and failure. The current standard for rejection monitoring in transplanted recipients is regular blood creatinine testing and kidney biopsies. Creatinine doesn't detect rejection until damages had occurred, causing some amount of kidney failure, and kidney biopsies are only done at set timepoints. A new test called CXCL10 is shown to be more effective in detecting rejection from previous research and can be done as often as needed. Therefore, The investigators are doing this randomized trial to test CXCL10 as part of clinical care and to help design a larger national clinical trial in the future.

Official title: A Pilot Clinical Trial to Evaluate the Feasibility and Acceptability of: A Prospective, Unblinded, Randomized-controlled, Multicenter Biomarker Intervention Trial of a Urinary CXCL10 Clinical Surveillance Program in Pediatric Kidney Transplant Recipients for Early Ascertainment and Treatment of Subclinical Allograft Inflammation and Preservation of Kidney Transplant Function

Key Details

Conditions

Interventions

Locations (3)